Clinical trials: Stage IV Non-small Cell Lung Cancer
Non-small Cell Lung Cancer (NSCLC)
Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)
The primary objective of the study is to compare sacituzumab tirumotecan combined with pembrolizumab to pembrolizumab alone with respect to overall survival (OS).
- Trial name
- TroFuse-007 (NCT06170788)
- Testing
- Sacituzumab tirumotecan, Pembrolizumab, Supportive care measures
- Where
- 220 sites in United States, Argentina and 24 more
- Volunteers
- 614 people
- Sponsor
- Merck Sharp & Dohme LLC
Lung Cancer, Non-Small Cell
Study of Pazopanib and Pemetrexed in Advanced Non-small Cell Lung Cancer
The main purpose of this study is to determine whether the combination of pazopanib and pemetrexed is safe and effective in the treatment of advanced non-small cell lung cancer (NSCLC).
- Trial name
- NCT00871403
- Testing
- pazopanib and pemetrexed, pemetrexed and cisplatin
- Where
- 2 sites in Denmark, United Kingdom
- Volunteers
- 107 people
- Sponsor
- GlaxoSmithKline
Non-Squamous Non-Small Cell Lung Cancer
A Study of Atezolizumab Compared With Docetaxel in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Failed Platinum-Containing Therapy
This global, multicenter, open-label, randomized, controlled study evaluated the efficacy and safety of atezolizumab (an anti-programmed death-ligand 1 [anti-PD-L1] antibody)compared with docetaxel in participants with locally…
- Trial name
- OAK (NCT02008227)
- Testing
- Atezolizumab, Docetaxel
- Where
- 208 sites in United States, Argentina and 29 more
- Volunteers
- 1,225 people
- Sponsor
- Hoffmann-La Roche
Metastatic or Incurable Non-small Cell Lung Cancer, Relapsed, Refractory Melanoma
RTA 408 in the Treatment of Advanced Solid Tumors (NSCLC & Melanoma) - DISCOVER
This proposed first-in-human study (408-C-1303) is designed to assess the safety, maximum tolerated dose, pharmacodynamics, and pharmacokinetics of omaveloxolone (RTA 408) in patients with advanced solid tumors that are…
- Trial name
- DISCOVER (NCT02029729)
- Testing
- omaveloxolone
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Biogen
Non Small Cell Lung Cancer
D-1553 Tablet Versus Docetaxel Injection for KRAS G12C Mutation-positive Locally Advanced or Metastatic Non-small Cell Lung Cancer After Prior Standard Therapy Failure
The purpose of this project is to evaluate progression-free survival (PFS) of D-1553 Tablet versus Docetaxel Injection in subjects with prior standard therapy failure kirsten rat sarcoma viral oncogene (KRAS) G12C mutation…
- Trial name
- NCT06300177
- Testing
- D-1553 Tablet, Docetaxel injection
- Where
- 86 sites in China
- Volunteers
- 522 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
ILKN421H Plus Pembrolizumab in Advanced Non-Small Cell Lung Cancer
This is a multicenter, open-label, phase II study to evaluate the safety, tolerability, clinical activity, and pharmacokinetics of ILKN421H in combination with pembrolizumab in participants with locally advanced or metastatic…
- Trial name
- NCT07452224
- Testing
- ILKN421H, Pembrolizumab
- Where
- 2 sites in United States
- Volunteers
- 80 people
- Sponsor
- iLeukon Therapeutics, Inc.
Non-Small-Cell Lung Carcinoma
A Study of AZD2936 Anti-TIGIT/Anti-PD-1 Bispecific Antibody in Participants With Advanced or Metastatic NSCLC
This is a Phase I/II study designed to evaluate if experimental anti-TIGIT/anti-PD-1 bispecific antibody rilvegostomig (AZD2936) is safe, tolerable and efficacious in participants with Advanced or Metastatic Non-small Cell Lung…
- Trial name
- ARTEMIDE-01 (NCT04995523)
- Testing
- AZD2936
- Where
- 40 sites in United States, Australia and 14 more
- Volunteers
- 212 people
- Sponsor
- AstraZeneca
Lung Neoplasms, Carcinoma, Non-Small-Cell Lung
A Study to Evaluate SHR-1210 in Patients With Advanced or Metastatic NSCLC
This is an open-label, single-arm, multi-center, phase 2 Study to evaluate SHR-1210(anti-PD-1 antibody) in in adult Chinese patients with advanced or metastatic non-small cell lung cancer who failed or progressed to prior…
- Conditions
- Lung Neoplasms, Carcinoma, Non-Small-Cell Lung, Respiratory Tract Neoplasms Nec, Lung Disease
- Trial name
- NCT03085069
- Testing
- SHR-1210
- Where
- China
- Volunteers
- 146 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Carcinoma, Non-Small-Cell Lung
A Study of Atezolizumab (Tecentriq) to Investigate Long-term Safety and Efficacy in Previously-treated Participants With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)
This is a Phase III/IV, single-arm, multicenter study of the long-term safety and efficacy of atezolizumab treatment in participants with Stage IIIb or Stage IV NSCLC who have progressed after standard systemic chemotherapy…
- Trial name
- TAIL (NCT03285763)
- Testing
- Atezolizumab
- Where
- 111 sites in Argentina, Brazil and 22 more
- Volunteers
- 619 people
- Sponsor
- Hoffmann-La Roche
Metastatic Non Small Cell Lung Cancer
Dacomitinib for Treatment of Patients in India With Metastatic Non Small Cell Lung Cancer With EGFR Activating Mutations
This is a Phase 4, open label, single arm, multi-center, prospective clinical trial of dacomitinib that will be performed in India.
- Trial name
- NCT04511533
- Testing
- Dacomitinib
- Where
- 15 sites in India
- Volunteers
- 101 people
- Sponsor
- Pfizer
Non-Squamous Non-Small Cell Lung Cancer
An Observational Study of Erlotinib (Tarceva) as Second-line Treatment in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer After Failure of Pemetrexed in First-line Therapy
This prospective, multicenter observational study will evaluate the efficacy, safety, and tolerability of Tarceva (erlotinib) as second-line treatment in patients with locally advanced or metastatic non-small cell lung cancer…
- Trial name
- TIME (NCT01664533)
- Testing
- Erlotinib
- Where
- 21 sites in Belgium
- Volunteers
- 57 people
- Sponsor
- Hoffmann-La Roche
NSCLC Stage IIIB, NSCLC Stage IV
Study of Autologous Immune Killer Cells in Patients With Late Stage Hepatocellular Carcinoma or Lung Cancer
This is a phase I clinical study. Blood is drawn from the patient and brought to our laboratory for isolation of immune cells. These immune cells are then proliferated over a two week period and used to produce our patented…
- Conditions
- NSCLC Stage IIIB, NSCLC Stage IV, Hepatocellular Carcinoma by BCLC Stage, Lung Cancer
- Trial name
- NCT03515252
- Testing
- Immune Killer Cells (IKC)
- Volunteers
- 20 people
- Sponsor
- Ivy Life Sciences, Co., Ltd
Non-small Cell Lung Cancer, Breast Cancer
Safety Study of Imexon Plus Docetaxel in Lung, Breast or Prostate Cancer Patients
Protocol AMP-010 is a Phase 1b study of imexon plus docetaxel for patients with previously treated breast cancer, previously treated lung cancer or hormone refractory prostate cancer.
- Conditions
- Non-small Cell Lung Cancer, Breast Cancer, Prostate Cancer
- Trial name
- NCT00327288
- Testing
- imexon, docetaxel
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- AmpliMed Corporation
Metastatic Non-small Cell Lung Cancer, Locally Advanced Urothelial Cancer
A Study of INCMGA00012 in Participants With Selected Solid Tumors (POD1UM-203)
The purpose of this study is to assess the clinical activity and safety of INCMGA00012 in participants with advanced solid tumors where the efficacy of PD-1 inhibitors has previously been established.
- Conditions
- Metastatic Non-small Cell Lung Cancer, Locally Advanced Urothelial Cancer, Metastatic Urothelial Cancer, Unresectable Melanoma
- Trial name
- NCT03679767
- Testing
- Retifanlimab
- Where
- 52 sites in United States, Austria and 6 more
- Volunteers
- 121 people
- Sponsor
- Incyte Corporation
Non Small Cell Lung Cancer
Investigation of Safety and Efficacy of SB Injection in Patients With Advanced and Metastatic Non-small Cell Lung Cancer
The purpose of this study is to determine efficacy of SB injection in Non Small Cell Lung Cancer.
- Trial name
- NCT01305967
- Testing
- SB injection
- Where
- 3 sites in South Korea
- Volunteers
- 20 people
- Sponsor
- SBPharmaceutical IND, Co., LTD
Lung Cancer
Early Access Program of Lazertinib in Republic of Korea
This early access program will be conducted to provide access to Lazertinib for adult patients with locally advanced or metastatic Non-small Cell Lung Cancer (NSCLC) with T790M mutation-positive after 1st/2nd generation EGFR TKIs…
- Trial name
- NCT04829422
- Testing
- Lazertinib 240 mg
- Sponsor
- Yuhan Corporation
Non Small Cell Lung Cancer
Safety and Efficacy of Talactoferrin in Addition to Standard Chemotherapy in Patients With Non-small Cell Lung Cancer
The purpose of the study is to determine whether the combination of talactoferrin, carboplatin and paclitaxel improves progression free survival and overall survival in patients with non-small cell lung cancer compared to the…
- Trial name
- FORTIS-C (NCT00706862)
- Testing
- Talactoferrin
- Where
- 6 sites in United States
- Volunteers
- 1,100 people
- Sponsor
- Agennix
Carcinoma, Non-Small-Cell Lung
Safety and Efficacy Study of CC-486 With MK-3475 to Treat Locally Advanced or Metastatic Non-small Cell Lung Cancer
The purpose of this study is to determine whether the combination therapy of CC-486 (oral azacitidine) and pembrolizumab provides improved patient outcomes compared to pembrolizumab alone in patients with previously treated…
- Trial name
- NCT02546986
- Testing
- CC-486, Pembrolizumab
- Where
- 33 sites in United States, France and 4 more
- Volunteers
- 100 people
- Sponsor
- Celgene
Non-Small Cell Lung Cancer
A Study of the Effect of R1507 in Combination With Tarceva (Erlotinib) on Progression-Free Survival in Patients With Stage IIIb/IV Non-Small Cell Lung Cancer (NSCLC) Having Received Tarceva Monotherapy.
This single arm study in patients with advanced Stage IIIb/IV NSCLC who have progressive disease after deriving clinical benefit (defined as response or stable disease after 12 weeks) from second or third line Tarceva monotherapy…
- Trial name
- NCT00773383
- Testing
- RG1507, erlotinib [Tarceva]
- Where
- 16 sites in United States, Canada and 2 more
- Volunteers
- 35 people
- Sponsor
- Hoffmann-La Roche
Neoplasms, Metastatic Cancer
Study of Niraparib, TSR-022, Bevacizumab, and Platinum-Based Doublet Chemotherapy in Combination With TSR-042
Part A: To test the safety and tolerability of combination therapy with Niraparib and TSR-042 and to establish a safe dose that will be used in a Phase 2 study.
- Conditions
- Neoplasms, Metastatic Cancer, Advanced Cancer, Solid Tumor
- Trial name
- NCT03307785
- Testing
- Niraparib, TSR-042, Carboplatin-Paclitaxel
- Where
- 8 sites in United States
- Volunteers
- 60 people
- Sponsor
- Tesaro, Inc.